LICENSE AGREEMENT by and among COHERUS BIOSCIENCES, INC., BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE CORPORATION, AND BAXTER HEALTHCARE SA dated August 30, 2013License Agreement • August 5th, 2014 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • New York
The following general matters related to the subject matter of this Agreement may be disclosed by Coherus to potential investors, collaboration partners and underwriters, on a non-confidential basis and without the prior written consent of Licensee:
SELEXIS COMMERCIAL LICENSE AGREEMENT ENTERED INTO WITH BIOGENERICS, INC.Commercial License Agreement • August 5th, 2014 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Commercial License Agreement (the “Agreement”) is made effective on April 8, 2011 (the “Effective Date”), by and between SELEXIS SA, 18 chemin des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland SA (“Selexis”) and BIOGENERICS, INC. 555 Bryant Street, Ste 266, Palo Alto, CA 94301 (“COMPANY”).
LICENSE AGREEMENT by and between BIOGENERICS, INC. and DAIICHI SANKYO COMPANY, LIMITED dated January 23rd, 2012License Agreement • August 5th, 2014 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • New York
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
DISTRIBUTION AGREEMENTDistribution Agreement • August 5th, 2014 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • New York
THIS DISTRIBUTION AGREEMENT (the “Agreement”) is made and entered into as of December 26, 2012 (the “Effective Date”) between COHERUS BIOSCIENCES, INC., a Delaware corporation with a principal place of business at 201 Redwood Shores Parkway, Suite 200, Redwood City, California 94065, United States of America (“Coherus”), and OROX PHARMACEUTICALS B.V., a Caraçao company with a principal place of business at Schottegatweg Oost 10, unit 1A1, Curaçao (“Distributor”). Coherus and Distributor are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
CONFIDENTIAL NON-EXCLUSIVE LICENSE AGREEMENT [“Cabilly Patents”]Non-Exclusive License Agreement • August 5th, 2014 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • California
This Non-Exclusive License Agreement (“Agreement”) is effective as of July 10, 2013 (“Effective Date”) by and between Genentech, Inc., a corporation having its principal place of business at 1 DNA Way, South San Francisco, California 94080 (hereinafter “Genentech”) and Coherus Biosciences, Inc., a corporation having its principal place of business at 201 Redwood Shores Parkway, Suite 200, Redwood City, CA 94065 (hereinafter “Coherus”).
FIRST AMENDMENT TO LICENSE AGREEMENTLicense Agreement • August 5th, 2014 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT (this “Amendment”) is made and entered into as of this 7th day of February, 2014 (the “Effective Date”) by and among Coherus Biosciences, Inc., a Delaware corporation with a principal place of business at 201 Redwood Shores Parkway, Suite 200, Redwood City, California 94065, United States of America (“Coherus”), on the one hand, and Baxter International, Inc., a Delaware corporation with a principal place of business at 1 Baxter Parkway, Deerfield, IL 60015, United States of America (“BII”), Baxter Healthcare SA, a Swiss corporation with a principal place of business at Postfach 8010 Zurich, Switzerland (“BHSA”) and Baxter Healthcare Corporation, a Delaware corporation with a principal place of business at 1 Baxter Parkway, Deerfield, IL 60015, United States of America (“BHC” and, together with BII and BHSA, “Baxter’’), on the other hand to amend the terms of that certain License Agreement between Coherus and Baxter dated August 30, 2013 (the “License Agreement”).
